Address of Chair and CEO to AGM
Filed with ASX · · 10 pages · English
Earlier from Acrux
- Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
- Investor Presentation - Acrux FY23 Results
- Appendix 4E and FY23 Annual Report
- Activities Statement and Appendix 4C
- Acruxs seventh generic dossier accepted by FDA for review
Later from Acrux
- Appendix 4C and Activities Statement
- Appendix 4D and Half Year Accounts
- Investor Presentation Half Year Accounts
- Launch of Dapsone 5%, Gel in the United States
- Acrux presentation at Hidden Gems in Lifesciences Forum
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux